In some aspects, the present disclosure provides methods for enriching amplicons, or amplification products, comprising a concatemer of at least two or more copies of a target polynucleotide. In some embodiments, a method comprises sequencing the amplicons comprising at least two or more copies of a target polynucleotide. In some embodiments, the target polynucleotides comprise sequences resulting from chromosome rearrangement, including but not limited to point mutations, single nucleotide polymorphisms, insertions, deletions, and translocations including fusion genes. In some aspects, the present disclosure provides compositions and reaction mixtures useful in the described methods.

In some aspects, the present disclosure provides methods for enriching amplicons, or amplification products, comprising a concatemer of at least two or more copies of a target polynucleotide. In some embodiments, a method comprises sequencing the amplicons comprising at least two or more copies of a target polynucleotide. In some embodiments, the target polynucleotides comprise sequences resulting from chromosome rearrangement, including but not limited to point mutations, single nucleotide polymorphisms, insertions, deletions, and translocations including fusion genes. In some aspects, the present disclosure provides compositions and reaction mixtures useful in the described methods.

Described are methods of analyzing cell free DNA based on combining analysis of cfDNA methylation with analysis of the cfDNA nucleosome footprint and/or with analysis of cfDNA copy number alteration. The diagnostic performance of these methods, in particular relating to early or earlier stage diseases or disorders, is increased compared to the diagnostic performance of the individual cfDNA analysis methods.

Described are methods of analyzing cell free DNA based on combining analysis of cfDNA methylation with analysis of the cfDNA nucleosome footprint and/or with analysis of cfDNA copy number alteration. The diagnostic performance of these methods, in particular relating to early or earlier stage diseases or disorders, is increased compared to the diagnostic performance of the individual cfDNA analysis methods.

The present invention discloses a method of real-time quantification of a target nucleic acid in a sample by constructing a reference table of copy number vs. designated parameter from reference samples which sharing the same nucleic acid sequences with the target nucleic acid. After that, obtain the designated parameter of the target sample and get the copy number by looking up and interpolating to the reference table. The object of the present invention is in particular provide methods for the quantification of the target nucleic acid which the target nucleic acid is quantified independently without comparing it to the standard controls by using a calibration curve. This invention will not only provide a new quantifying method, but will also propose a new standard operational method that eliminates the variations accompanying amplification efficiency, polymerase activity, primer concentrations, and instrument variations.

The present invention discloses a method of real-time quantification of a target nucleic acid in a sample by constructing a reference table of copy number vs. designated parameter from reference samples which sharing the same nucleic acid sequences with the target nucleic acid. After that, obtain the designated parameter of the target sample and get the copy number by looking up and interpolating to the reference table. The object of the present invention is in particular provide methods for the quantification of the target nucleic acid which the target nucleic acid is quantified independently without comparing it to the standard controls by using a calibration curve. This invention will not only provide a new quantifying method, but will also propose a new standard operational method that eliminates the variations accompanying amplification efficiency, polymerase activity, primer concentrations, and instrument variations.

A method determines a number of copies of a DNA sequence that is present in a fluid. The method includes a division step, a setting up step, an identification step, and an evaluation step. In the division step, at least some of the fluid is divided into at least two compartments. In the setting up step, a reaction condition is set up for the fluid divided into the at least two compartments in order to allow a reaction in each of the at least two compartments and to obtain a reaction result in each case. In the identification step, a signal, for example an optical signal, is identified that represents the reaction results of the reactions that may have taken place in the compartments. In the evaluation step, the optical signal is evaluated in order to determine the number of copies.

A method determines a number of copies of a DNA sequence that is present in a fluid. The method includes a division step, a setting up step, an identification step, and an evaluation step. In the division step, at least some of the fluid is divided into at least two compartments. In the setting up step, a reaction condition is set up for the fluid divided into the at least two compartments in order to allow a reaction in each of the at least two compartments and to obtain a reaction result in each case. In the identification step, a signal, for example an optical signal, is identified that represents the reaction results of the reactions that may have taken place in the compartments. In the evaluation step, the optical signal is evaluated in order to determine the number of copies.

Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.